Warfarin: Indications, risks and drug interactions

Australian Family Physician

Volumn 39, Issue 7, 2010, Pages 476-479

  Tadros, Rami ^a   Shakib, Sepehr ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Atrial fibrillation; Heart valve prosthesis; International Normalised Ratio; Venous thromboembolism; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; CYTOCHROME P450; VITAMIN K GROUP; WARFARIN;

ARTICLE; DRUG ANTAGONISM; DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HEART VALVE PROSTHESIS; HUMANS; INTERNATIONAL NORMALIZED RATIO; RISK FACTORS; VENOUS THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 77957275340     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8-21s.
2. Hart GH, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.
3. Singer De, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009;151:297-305.
4. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
5. Therapeutic Guidelines: Cardiovascular. 5th edn. Melbourne: Therapeutic Guidelines Limited, 2008.
6. Australian Medicines Handbook. 11th edn. Adelaide: Australian Medicines Handbook, 2010.
7. Buller HR, Agnelli G, Hull HR, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:401-28s.
8. Agnelli G, Becattini C. Treatment of DVT: How long is enough and how do you predict recurrence. J Thromb Thrombolysis 2008;25:37-44.
9. Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008;179:417-26.
10. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635-41.
11. Salem D, O'Gara P, Madias C, Pauker S. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edn. Chest 2008;133:593-629s.
12. Appelboam R, Thomas EO. Warfarin and intracranial haemorrhage. Blood Rev 2009;23:1-9.
13. Butchart EG, Gohlke-Barwolf C, Antunes MJ, et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005;26:2463-71.
14. Garwood CL, Corbett TL. Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls. Ann Pharmacother 2008;42:523-32.
15. MIMS Australia, 2010. Available at www.mims.com.au.
16. Ghose K, Ashton J, Rohan A. Possible interaction of roxithromycin with warfarin: updated review of ADR reports. Clin Drug Invest 1995;10:302-9.
17. Paulsen O, Nilsson LG, Saint-Salvi B, et al. No effect of roxithromycin on pharmacokinetic or pharmacodynamic properties of warfarin and its enantiomers. Pharmacol Toxicol 1988;63:215-20.
18. Holbrook A, Labiris R, Goldsmith CH, Ota K, Harb S, Sebaldt RJ. Influence of decision aids on patient preferences for anticoagulation therapy: a ranomized trial. CMAJ 2007;176:1583-7.
19. Thompson RG, Eccles MP, Steen IN, et al. A patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trial. Qual Saf Health Care 2007;16:216-23.